The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.
Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case
Felixthecat
CSN Member Posts: 37
This recently published finding might be of interest to those with advanced colon cancer. This case report indicates very favourable results:
Anticancer Res. 2009 May;29(5):1611-3.
Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
http://www.ncbi.nlm.nih.gov/pubmed/19443374?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Check JH, Dix E, Sansoucie L, Check D.
BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment. MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases. RESULTS: Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated. CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.
Anticancer Res. 2009 May;29(5):1611-3.
Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
http://www.ncbi.nlm.nih.gov/pubmed/19443374?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Check JH, Dix E, Sansoucie L, Check D.
BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment. MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases. RESULTS: Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated. CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.
Comments
-
-
Safe drug to use and little to no toxicity - a big PLUS
Another good thing about the drug is that is has a very good safety profile. It's been used in the same dose (200mg daily) by meningioma patients for up to 14 years. It's no-where near as toxic as chemotherapeutic drugs.
Certainly for those with advanced colon cancer it would beneficial to trial before additional colon surgery or before the existing cancer spreads to the brain and other vital organs. Some try and all the readily available treatment options and still don't make it so another viable and safe drug to use is a big PLUS for those patients.
This new findings stems from their earlier reserach indicating the drug's potential to treat a variety of cancers irrespective of progesterone receptor status:
Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity.
http://www.ncbi.nlm.nih.gov/pubmed/18225679
Discussion Boards
- All Discussion Boards
- 6 Cancer Survivors Network Information
- 6 Welcome to CSN
- 122.6K Cancer specific
- 2.8K Anal Cancer
- 456 Bladder Cancer
- 312 Bone Cancers
- 1.7K Brain Cancer
- 28.6K Breast Cancer
- 408 Childhood Cancers
- 28K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13.1K Head and Neck Cancer
- 6.4K Kidney Cancer
- 681 Leukemia
- 803 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 242 Multiple Myeloma
- 7.2K Ovarian Cancer
- 70 Pancreatic Cancer
- 493 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 743 Skin Cancer
- 659 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.4K Lifestyle Discussion Boards